REVOLUTION MEDICINES INC (RVMD)

US76155X1000 - Common Stock

56.78  -0.29 (-0.51%)

After market: 58.75 +1.97 (+3.47%)

Buy % Consensus

89

ChartMill assigns a Buy % Consensus number of 89% to RVMD. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 61.28. This target is 7.92% above the current price.
RVMD was analyzed by 21 analysts. The buy percentage consensus is at 89. So analysts seem to be very confident about RVMD.
In the previous month the buy percentage consensus was at a similar level.
RVMD was analyzed by 21 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 56.7854.5459.1661.2876.65 - -3.95% 4.19% 7.92% 34.99%
Up and Down Grades
Date Firm Action Rating
2024-11-07 Needham Maintains Buy -> Buy
2024-11-07 JP Morgan Maintains Overweight -> Overweight
2024-11-07 Piper Sandler Maintains Overweight -> Overweight
2024-11-07 HC Wainwright & Co. Maintains Buy -> Buy
2024-10-28 Guggenheim Maintains Buy -> Buy
2024-10-28 Needham Reiterate Buy -> Buy
2024-10-28 Oppenheimer Maintains Outperform -> Outperform
2024-10-25 Needham Reiterate Buy -> Buy
2024-10-24 Needham Reiterate Buy -> Buy
2024-10-07 Needham Reiterate Buy -> Buy
2024-09-27 Barclays Maintains Overweight -> Overweight
2024-08-12 HC Wainwright & Co. Reiterate Buy -> Buy
2024-08-08 Needham Maintains Buy -> Buy
2024-08-08 Wedbush Reiterate Outperform -> Outperform
2024-08-08 JP Morgan Maintains Overweight -> Overweight
2024-07-18 Barclays Maintains Overweight -> Overweight
2024-07-16 Needham Maintains Buy -> Buy
2024-07-16 Oppenheimer Maintains Outperform -> Outperform
2024-07-16 B of A Securities Maintains Buy -> Buy
2024-07-16 HC Wainwright & Co. Maintains Buy -> Buy
2024-07-12 Barclays Initiate Overweight
2024-07-08 Jefferies Initiate Buy
2024-05-13 HC Wainwright & Co. Reiterate Buy -> Buy
2024-05-09 Needham Reiterate Buy -> Buy
2024-05-09 Wedbush Maintains Outperform -> Outperform
2024-04-12 Needham Maintains Buy -> Buy
2024-04-12 Oppenheimer Maintains Outperform -> Outperform
2024-04-10 Raymond James Upgrade Outperform -> Strong Buy
2024-04-08 Needham Maintains Buy -> Buy
2024-03-11 Piper Sandler Initiate Overweight